The new product is a type of intramedullary nail, which is a rod that is inserted into a badly broken bone to keep the fragments together, according to the report.
The FDA clearance means that the agency feels that this device is similar to other products on the market and does not require clinical trials.
Read the Commercial Appeal’s report about NovaLign’s new intramedullary nail.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
